Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: RT who wrote (21736)	5/8/1999 1:33:00 PM
From: VLAD	Respond to of 23519

RT, I don't believe that any one here disagrees with the points you make concerning Alibra and there is no doubt in my mind that there will be no deal for MUSE that doesn't include Alibra. On the other hand think about this: Vivus has no deal with A/Z or Janssen regarding Alibra. If they don't give Vivus some decent deals/milestones to market Alibra internationally then they will be screwed if Vivus brokers new deals with other large pharmaceuticals for Alibra in those territories. They way I see it we can expect some HEFTY milestone payments from both A/Z and Janssen to market Alibra. I expect $10M from each for their respective territories. How does adding $20M or more to Vivus' cash position make you feel?